Cost effectiveness of different cervical screening strategies in Islamic Republic of Iran: a middle-income country with a low incidence rate of cervical cancer

Nahvijou, A., Daroudi, R., Tahmasebi, M., Hashemi, F. A., Rezaei Hemami, M., Sari, A. A., Marenani, A. B. and Zendehdel, K. (2016) Cost effectiveness of different cervical screening strategies in Islamic Republic of Iran: a middle-income country with a low incidence rate of cervical cancer. PLoS ONE, 11(6), e0156705. (doi: 10.1371/journal.pone.0156705) (PMID:27276093) (PMCID:PMC4898767)

[img]
Preview
Text
128564.pdf - Published Version
Available under License Creative Commons Attribution.

366kB

Abstract

Objective: Invasive cervical cancer (ICC) is the fourth most common cancer among women worldwide. Cervical screening programs have reduced the incidence and mortality rates of ICC. We studied the cost-effectiveness of different cervical screening strategies in the Islamic Republic of Iran, a Muslim country with a low incidence rate of ICC. Methods: We constructed an 11-state Markov model, in which the parameters included regression and progression probabilities, test characteristics, costs, and utilities; these were extracted from primary data and the literature. Our strategies included Pap smear screening and human papillomavirus (HPV) DNA testing plus Pap smear triaging with different starting ages and screening intervals. Model outcomes included lifetime costs, life years gained, quality-adjusted life years (QALY), and incremental cost-effectiveness ratios (ICERs). One-way sensitivity analysis was performed to examine the stability of the results. Results: We found that the prevented mortalities for the 11 strategies compared with no screening varied from 26% to 64%. The most cost-effective strategy was HPV screening, starting at age 35 years and repeated every 10 years. The ICER of this strategy was $8,875 per QALY compared with no screening. We found that screening at 5-year intervals was also cost-effective based on GDP per capita in Iran. Conclusion: We recommend organized cervical screening with HPV DNA testing for women in Iran, beginning at age 35 and repeated every 10 or 5 years. The results of this study could be generalized to other countries with low incidence rates of cervical cancer.

Item Type:Articles
Additional Information:This work was part of a PhD dissertation supported by Iran University of Medical Sciences (Grant No.: IUMS/SHMIS-1391/128).
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Rezaeihemami, Dr Mohsen
Authors: Nahvijou, A., Daroudi, R., Tahmasebi, M., Hashemi, F. A., Rezaei Hemami, M., Sari, A. A., Marenani, A. B., and Zendehdel, K.
College/School:College of Medical Veterinary and Life Sciences > School of Health & Wellbeing > Health Economics and Health Technology Assessment
Journal Name:PLoS ONE
Publisher:Public Library of Science
ISSN:1932-6203
ISSN (Online):1932-6203
Copyright Holders:Copyright © 2016 Nahvijou et al.
First Published:First published in PLoS ONE 11(6): e0156705
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record